2025 - Biomarker Testing Strategies for Enhancing Ultrasensitive Immunoassays

In drug development, ultrasensitive bioanalytical platforms are increasingly in demand, especially in neuroscience, where analytes are often present at very low concentrations.
.KCAS Bio addresses this demand with technologies ranging from dedicated platforms to ultra-sensitive kits on conventional systems.
The NULISA™ / Argo™ HT platform is a new, cutting-edge technology with strong potential in ultra-sensitive biomarker detection and targeted proteomics.
In this webinar, the featured speakers will share initial data exploring the use of the NULISA™ / Argo™ HT platform for developing a custom assay kit and evaluating its ability to improve the method sensitivity for a target engagement biomarker, including a comparison with a transferred Simoa® method that proved insufficiently sensitive in CSF and plasma from patients with a rare neurodegenerative disease.
Early results showed that the calibration curve exhibited enhanced sensitivity, and optimized assay conditions further increased detection capability.
Viewers will gain insights into developing, optimizing and applying next-generation ultra-sensitive technology for challenging biomarker detection.
Register now to learn how NULISA™ / Argo™ HT can enhance assay sensitivity and support neurodegenerative drug development.
Keywords: Assay Development, Bioanalytical Testing, Biomarker Discovery, Biomarkers, Clinical Research, CNS, Drug Development, Immunoassays, Laboratory Technology, Neurodegenerative Disease, Therapeutic Areas, Translational Research